PurposeWe sought to determine whether the combination of ixabepilone plus capecitabine improvedoverall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer(MBC) previously treated with anthracyclines and taxanes.Patients and MethodsA total of 1,221 patients with MBC previously treated with anthracycline and taxanes wererandomly assigned to ixabepilone (40 mg/m2 intravenously on day 1) plus capecitabine (2,000mg/m2 orally on days 1 through 14) or capecitabine alone (2,500 mg/m2 on the same schedule)given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR)for death.ResultsThere was no significant difference in OS between the combination and capecitabine monotherapyarm, the primary end point (median, 16.4 v 15.6 months; HR 0.9; 95% CI, 078 to 1.03;P .1162). The arms were well balanced with the exception of a higher prevalence of impairedperformance status (Karnofsky performance status 70% to 80%) in the combination arm (32% v25%). In a secondary Cox regression analysis adjusted for performance status and otherprognostic factors, OS was improved for the combination (HR 0.85; 95% CI, 0.75 to 0.98;P .0231). In 79% of patients with measurable disease, the combination significantly improvedprogression-free survival (PFS; median, 6.2 v 4.2 months; HR 0.79; P .0005) and response rate(43% v 29%; P .0001). Grade 3 to 4 neuropathy occurred in 24% treated with the combination,but was reversible.ConclusionThis study confirmed a previous trial demonstrating improved PFS and response for theixabepilone-capecitabine combination compared with capecitabine alone, although this did not result inimproved survival.

randomised phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane / Ja, Sparano; E., Vrdoljak; O., Rixe; B., Xu; A., Manikhas; C., Medina; SC Da, Costa; J., Ro; G., Rubio; M., Rondinon; G., Perez Manga; R., Peck; V., Poulart; Conte, Pierfranco. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 28:(2010), pp. 3256-3263. [10.1200/JCO.2009.24.4244]

randomised phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

CONTE, Pierfranco
2010-01-01

Abstract

PurposeWe sought to determine whether the combination of ixabepilone plus capecitabine improvedoverall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer(MBC) previously treated with anthracyclines and taxanes.Patients and MethodsA total of 1,221 patients with MBC previously treated with anthracycline and taxanes wererandomly assigned to ixabepilone (40 mg/m2 intravenously on day 1) plus capecitabine (2,000mg/m2 orally on days 1 through 14) or capecitabine alone (2,500 mg/m2 on the same schedule)given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR)for death.ResultsThere was no significant difference in OS between the combination and capecitabine monotherapyarm, the primary end point (median, 16.4 v 15.6 months; HR 0.9; 95% CI, 078 to 1.03;P .1162). The arms were well balanced with the exception of a higher prevalence of impairedperformance status (Karnofsky performance status 70% to 80%) in the combination arm (32% v25%). In a secondary Cox regression analysis adjusted for performance status and otherprognostic factors, OS was improved for the combination (HR 0.85; 95% CI, 0.75 to 0.98;P .0231). In 79% of patients with measurable disease, the combination significantly improvedprogression-free survival (PFS; median, 6.2 v 4.2 months; HR 0.79; P .0005) and response rate(43% v 29%; P .0001). Grade 3 to 4 neuropathy occurred in 24% treated with the combination,but was reversible.ConclusionThis study confirmed a previous trial demonstrating improved PFS and response for theixabepilone-capecitabine combination compared with capecitabine alone, although this did not result inimproved survival.
28
3256
3263
randomised phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane / Ja, Sparano; E., Vrdoljak; O., Rixe; B., Xu; A., Manikhas; C., Medina; SC Da, Costa; J., Ro; G., Rubio; M., Rondinon; G., Perez Manga; R., Peck; V., Poulart; Conte, Pierfranco. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 28:(2010), pp. 3256-3263. [10.1200/JCO.2009.24.4244]
Ja, Sparano; E., Vrdoljak; O., Rixe; B., Xu; A., Manikhas; C., Medina; SC Da, Costa; J., Ro; G., Rubio; M., Rondinon; G., Perez Manga; R., Peck; V., Poulart; Conte, Pierfranco
File in questo prodotto:
File Dimensione Formato  
3256.full.pdf

non disponibili

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 271.6 kB
Formato Adobe PDF
271.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/721645
Citazioni
  • ???jsp.display-item.citation.pmc??? 53
  • Scopus 197
  • ???jsp.display-item.citation.isi??? 168
social impact